Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07783802 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Name: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event — clinical trial record (NCT07783802)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CLARITY-CRP

StatusNot Yet Recruiting

PhasePhase 2

SponsorEli Lilly and Company

Started2026-09

View on ClinicalTrials.gov ↗

The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months.

Trial Details

NCT Number	NCT07783802
Lead Sponsor	Eli Lilly and Company
Conditions	Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Enrollment	120 participants
Start Date	2026-09
Primary Completion	2027-05 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-25